Aravive, Inc. (ARAV): Price and Financial Metrics


Aravive, Inc. (ARAV): $4.15

0.09 (+2.22%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ARAV to Watchlist
Sign Up

Industry: Biotech


Ranked

of 502

in industry

ARAV POWR Grades


  • Sentiment is the dimension where ARAV ranks best; there it ranks ahead of 67.04% of US stocks.
  • ARAV's strongest trending metric is Value; it's been moving up over the last 31 weeks.
  • ARAV ranks lowest in Momentum; there it ranks in the 9th percentile.

ARAV Stock Summary

  • Aravive Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 12.27% of US listed stocks.
  • As for revenue growth, note that ARAV's revenue has grown 94.53% over the past 12 months; that beats the revenue growth of 93.71% of US companies in our set.
  • Aravive Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -40.36%, greater than the shareholder yield of just 7.15% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Aravive Inc are ALT, ZSAN, SPOK, LIFE, and XCUR.
  • ARAV's SEC filings can be seen here. And to visit Aravive Inc's official web site, go to aravive.com.

ARAV Valuation Summary

  • In comparison to the median Healthcare stock, ARAV's price/earnings ratio is 109.12% lower, now standing at -3.1.
  • ARAV's price/sales ratio has moved NA NA over the prior 89 months.
  • Over the past 89 months, ARAV's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for ARAV.

Stock Date P/S P/B P/E EV/EBIT
ARAV 2021-06-18 17.1 1.5 -3.7 -1.0
ARAV 2020-07-10 57.9 3.0 -7.3 -5.1
ARAV 2019-09-26 15.6 1.8 -1.5 -0.9
ARAV 2019-08-20 11.3 1.3 -1.1 -0.5
ARAV 2015-10-21 NA 1.4 -4.2 -1.2
ARAV 2014-04-17 NA -12.5 -31.9 -31.4

ARAV Price Target

For more insight on analysts targets of ARAV, see our ARAV price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $22.50 Average Broker Recommendation 1.3 (Strong Buy)

ARAV Stock Price Chart Interactive Chart >

Price chart for ARAV

ARAV Price/Volume Stats

Current price $4.15 52-week high $9.95
Prev. close $4.06 52-week low $3.97
Day low $4.06 Volume 77,400
Day high $4.21 Avg. volume 372,527
50-day MA $4.98 Dividend yield N/A
200-day MA $5.68 Market Cap 85.96M

Aravive, Inc. (ARAV) Company Bio


Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, triple negative breast cancer, acute myeloid leukemia, and pancreatic cancer. The company has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.


ARAV Latest News Stream


Event/Time News Detail
Loading, please wait...

ARAV Latest Social Stream


Loading social stream, please wait...

View Full ARAV Social Stream

Latest ARAV News From Around the Web

Below are the latest news stories about Aravive Inc that investors may wish to consider to help them evaluate ARAV as an investment opportunity.

Aravive to Participate in Fireside Chat at 2021 BTIG Biotechnology Conference

HOUSTON, July 27, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the 2021 BTIG Biotechnology Conference on August 9, 2021, at 9:30 AM ET. Aravive will also be participating in one-on-one

Yahoo | July 27, 2021

Aravive Achieves Second Development Milestone from 3D Medicines

Milestone is Based on Approval of 3D Medicines’ IND in China to Participate in Aravive’s AVB-500 (3D-299) Phase 3 Clinical Trial for Platinum Resistant Ovarian CancerHOUSTON, July 15, 2021 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that it achieved a $3 million development milestone payment from its licensee, 3D Medicines Inc. This milestone is based on the Center for Dr

Yahoo | July 15, 2021

Aravive to Participate in Fireside Chat at 2021 William Blair Biotech Focus Conference

HOUSTON, July 07, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DBAT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the 2021 William Blair Biotech Focus Conference on July 15, 2021, at 3:00 PM ET. Aravive will also be participating in one

Yahoo | July 7, 2021

Hedge Fund Sentiment Is Stagnant On Aravive, Inc. (ARAV)

In this article we will take a look at whether hedge funds think Aravive, Inc. (NASDAQ:ARAV) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from […]

Yahoo | June 29, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're back at it again with another look at the biggest pre-market stock movers for Friday as the perfect way to close out the week.

William White on InvestorPlace | June 25, 2021

Read More 'ARAV' Stories Here

ARAV Price Returns

1-mo -26.16%
3-mo -17.00%
6-mo -26.02%
1-year -29.66%
3-year -60.48%
5-year -93.89%
YTD -26.42%
2020 -58.74%
2019 288.35%
2018 -73.33%
2017 -85.23%
2016 20.26%

Continue Researching ARAV

Want to see what other sources are saying about Aravive Inc's financials and stock price? Try the links below:

Aravive Inc (ARAV) Stock Price | Nasdaq
Aravive Inc (ARAV) Stock Quote, History and News - Yahoo Finance
Aravive Inc (ARAV) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0752 seconds.